

## Title

# Haematology & Immunoglobulin Treatments

---

Reference Number: RDF2402-24

Date of Response: 08/04/24

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

*Q1. In the past 3 months, how many patients have received the following treatments (for any disease):*

- *Berinert (Human C1-esterase inhibitor)*
- *Cinryze (Human C1-esterase inhibitor)*
- *Firazyr (Icatibant)*
- *Icatibant - any brand except Firazyr*
- *Orladeyo (Bertralstat)*
- *Ruconest (Recombinant human C1-esterase inhibitor)*
- *Takhzyro (Lanadelumab)*

Trust answers: - 0 patients for all the above.

*Q2. In the past 3 months, how many patients have received the following immunoglobulin treatments (for any disease):*

Treatments	Number of patients
<i>Other Immunoglobulin</i>	8
<i>Intratect</i>	* <5
<i>Igymune</i>	9
<i>Kiovig</i>	15
<i>Octama</i>	* <5
<i>Privigen</i>	25
<i>Cutaquig</i>	0
<i>Cuvitru</i>	0
<i>Gammagard</i>	0
<i>Gammanorm</i>	0
<i>Hizentra</i>	0
<i>Hyqvia</i>	0
<i>Panzyga</i>	0
<i>Subgam</i>	0
<i>Any other normal immunoglobulin</i>	0

\* <5 Section 40 (2)

Please note that in accordance with Section 40 (2) where activity is 5 or less than 5, the Trust is unable to provide the exact information. We consider the data exempt on the following grounds:

The Trust considers that disclosure of the information risks identifying individuals.

The reason for this is that the number of patients for which this applies is very low.

This and the fact that the data requested relates to the RDUH Health NHS Trust only and therefore relates to patients treated in a specific location (rather than covering a larger geographical area), increases the risk of identification or self-identification.

The Trust's view is that s.40(2) is applicable because disclosure of information which could lead to a patient being identified would be a breach of the patient's rights under the Data Protection Act Data Protection Principles set out in Schedule 1 of the GDPR, namely Principle 1.